VP01 (C21)

Phase 2
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:

Drug Detail

VP01 (C21) is a first in class orally available low molecular weight angiotensin II receptor type 2 (AT2R) agonist that activates the “protective arm” of the renin angiotensin system (RAS). The compound has previously shown effects in the bleomycin and monocrotaline pulmonary fibrosis/PH models and is currently in clinical development for IPF, pulmonary fibrosis in systemic sclerosis and COVID-19.

Study Purpose

This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.

Find a Clinical Trial